Lynparza secures accelerated FDA review for metastatic castration-resistant prostate cancer
January 20, 2020Sales and Marketing Cancer, FDA, lynparza, pharma
Following the recommendation of the tablet formulation of the drug for use on the NHS in England and Wales, news …
Collaborating to realise the potential of precision medicine
January 20, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Precision Medicine, feature, pharma
Healthcare is an evolving continuum, and while traditional strategies have seen improvements to patient outcomes over time, voices in the …
US judge slashes Johnson & Johnson damages in Risperdal case
January 20, 2020Sales and Marketing Big Pharma, Johnson & Johnson, Johnson & Johnson talc powder
A judge in Philadelphia has reduced the amount of damages Johnson & Johnson was ordered to pay by a jury …
NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns
January 20, 2020Sales and Marketing Bayer, Cancer, NICE, Vitravki
UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …
WHO officials say Wuhan viral pneumonia outbreak can be passed from person to person
January 20, 2020Sales and Marketing China, Sars, Viral pneumonia, WHO, World Health Organisation, Wuhan Outbreak
The viral pneumonia outbreak that began in Wuhan China can spread between person to person, according to health experts at …
Ipsen appoints new Exec VP and Chief Medical Officer
January 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen, pharma
Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs …
Top Ten most popular articles on Pharmafile.com this week
January 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, European Commission, FDA, Pakistan, Sanofi, Teva
Pakistan is cracking down on corruption and has registered cases against 200 pharmaceutical companies, while in the US the FDA …
Japan welcomes approval of ViiV’s Dovato for HIV-1
January 17, 2020Medical Communications, Sales and Marketing Dovato, Japan, ViiV Healthcare, pharma
Japan’s Ministry of Health, Labour and Welfare (MHLW) has awarded marketing approval to ViiV Healthcare, a subsidiary of GSK, for …
UK trial aims to find treatments that can slow or reverse motor neurone disease
January 17, 2020Medical Communications MND, Motor Neurone, clinical trial, motor neurone disease, trial
A UK wide trial called MND-SMART has invited hundreds of people with motor neurone disease (MND) to participate. It will …
China’s viral pneumonia spreads to Japan
January 17, 2020Medical Communications China, Japan, Sars, Viral pneumonia, Wuhan, epidemic, pandemic, pneumonia
A recent strain of viral pneumonia has spread from China to Japan, prompting fears of a global pandemic. A man …
Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD
January 17, 2020Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma
Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
US-China trade deal sees changes on drug patents
January 16, 2020Business Services China, Chinese Drug Patents, Trade Deal, US Drug Patents, US-China Trade Deal
The US and China signed the first part of a broader trade pact that included setting up a system to …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
HIV infections fall by 73% in bi and gay British men
January 16, 2020Business Services AIDS, AIDS Epidemic, HIV, NHS, NHS England, PrEP, nhs scotland
Public Health England has released figures that show that HIV rates in bi and gay men have fallen by 73% …
NICE shoots down Keytruda in head and neck cancer over data concerns
January 16, 2020Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma
It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …
FDA approves Lannett’s cocaine-based nasal spray
January 15, 2020Research and Development FDA, Lannett, Numbrino, cocaine
It has been announced that the FDA has moved to approve Lannett Company’s Numbrino (cocaine hydrochloride) nasal solution for “the …
FDA panel votes against Nektar opioid painkiller
January 15, 2020Research and Development Bernie Opioids, Big Pharma, Trump opioids, opioid, opioid crisis, opioids, pharma
FDA unanimously voted against Nektar Therapeutics opioid pankiller (NKTR-181) for chronic lower back pain, prompting the company to withdraw its …
Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer
January 15, 2020Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma
NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …
Rochester Drug Cooperative ceases opioid sales following criminal charges
January 15, 2020Research and Development Bernie Sanders, Trump opioids, opioid, opioid crisis, opioids
The Rochester Drug Cooperative (RDC) has announced it will no longer distribute opioid medications after two of its executives were …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
